Research programme: matrix metalloproteinase 13 inhibitors - Wyeth

Drug Profile

Research programme: matrix metalloproteinase 13 inhibitors - Wyeth

Latest Information Update: 31 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Pfizer; Wyeth
  • Class
  • Mechanism of Action Matrix metalloproteinase 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 15 Oct 2009 Wyeth has been acquired by Pfizer
  • 31 Aug 2009 This programme is still in active development with Wyeth in the US
  • 21 Sep 2005 Preclinical trials in Osteoarthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top